Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
NCT ID: NCT00073385
Last Updated: 2005-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
225 participants
INTERVENTIONAL
2003-09-30
2004-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Purpose: This open-label randomized trial will evaluate whether combination therapy with Pivanex and docetaxel provides clinical benefit over docetaxel alone in patients with chemotherapy resistant non-small cell lung cancer.
Objectives:
* Compare the survival of patients with non-small cell lung cancer treated with combination therapy with Pivanex and docetaxel vs. docetaxel alone
* Compare the time to disease progression, tumor responses, and safety profile of patients with non-small cell lung cancer treated with combination therapy with Pivanex and docetaxel vs. docetaxel alone
Outline: This is a randomized, open-label, multicenter study in patients with non-small cell lung cancer who have previously been treated with no more than one prior platinum containing chemotherapy regimen. Patients are stratified by ECOG performance status (0-1 vs. 2), response to prior platinum based chemotherapy (progression vs. CR/PR/SD) and prior taxane therapy (yes vs. no). Patients are randomized to 1 of 2 treatment arms.
* Arm A: Patients receive the combination of Pivanex intravenously on Days 1-3 and docetaxel intravenously on Day 4. Treatment repeats every 21 days until disease progression or treatment withdrawal.
* Arm B: Patients receive docetaxel intravenously on Day 1. Treatment repeats every 21 days until disease progression or treatment withdrawal.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pivanex
Docetaxel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients previously treated with adjuvant or neoadjuvant chemotherapy (must be completed within 6 months prior to randomization) or
2. Patients who have received chemotherapy for advanced or metastatic lung cancer);
* Recurrent or progressive NSCLC (local, distant, or both) following initial chemotherapy);
* Measurable or non-measurable disease;
* Males and females, age =\> 18 years;
* Adequate renal function with creatinine =\> 1.5 mg/dl;
* Adequate liver function with alkaline phosphatase =\> 2.5 X upper limit of normal, SGOT, and SGPT =\> 1.5 X upper limit of normal; and total bilirubin =\> upper limit of normal;
* Adequate bone marrow function: platelets \> 100,000/mm3, hemoglobin =\> 9 g/dL, and absolute neutrophil count (ANC) =\> 1,500 cells/mm3;
* Able to give informed consent;
* Discontinuation of previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity;
* A predicted life expectancy of at least 12 weeks; and
* ECOG performance status of 0, 1, or 2.
Exclusion Criteria
* A second malignancy within the last 5 years other than curatively treated carcinoma-in-situ or non-melanoma skin cancer;
* Pregnant or lactating females (Females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control);
* Known HIV-positive patients;
* Acute medical problems, such as ischemic heart or lung disease or uncontrolled systemic infection;
* Patients with any underlying medical conditions or circumstance, which would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;
* Patients receiving investigational agents within 30 days of the screening visit;
* Known allergy to reagents in the study;
* Prior docetaxel therapy;
* Symptomatic or untreated brain metastases (Patients with brain metastases are eligible if they are clinically and neurologically stable for \> 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife; surgical resection) as determined by the investigator and either off corticosteroids or on a stable dose of corticosteroids).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Titan Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wilshire Oncology Medical Group
La Verne, California, United States
Hematology and Oncology Specialists, LLC
New Orleans, Louisiana, United States
HemOnCare
Brooklyn, New York, United States
Montefiore Medical Center, Department of Oncology
The Bronx, New York, United States
Gaston Hematology & Oncology Associates
Gastonia, North Carolina, United States
Rajiv Gandhi Cancer Institute & Research Center
New Delhi, , India
Regional Cancer Centre
Thiruvananthapuram, , India
University of Edinburgh, Edinburgh Cancer Centre
Edinburgh, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSCLC Clincal Trial
Identifier Type: -
Identifier Source: secondary_id
TTP-200-03-01
Identifier Type: -
Identifier Source: org_study_id